SCHEMBL34461723

SCHEMBL34461723

O=C(Cn1c2ccn(-c3ccccc3[N+](=O)[O-])c2c(=O)n2nnnc12)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.42
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HTT P42858 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ KDR P35968 3/20 0.37
▸ THRB P10828 2/20 0.36
▸ ENPP2 Q13822 1/20 0.35
▸ KAT2B Q92831 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34461739 0.89 TRPA1 (0.43) TRPA1MEN1KMT2AALDH1A1POLB
SCHEMBL34461722 0.85 TRPA1 (0.43) TRPA1MEN1KMT2AALDH1A1POLB
SCHEMBL34461716 0.85 TRPA1 (0.40) TRPA1KDM4ETP53MAPTAKR1B1
SCHEMBL34461724 0.83 GRIK1 (0.39) MEN1KMT2AALDH1A1POLB
SCHEMBL34461756 0.81 TRPA1 (0.39) TRPA1KDM4ETP53MAPTAKR1B1
SCHEMBL34461772 0.78 CYP1A2 (0.35) MEN1KMT2AALDH1A1POLBCYP1A2
SCHEMBL34461790 0.78 HCAR1 (0.33) KMT2AALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL34461735 0.74 TRPA1 (0.42) TRPA1MEN1KMT2AALDH1A1POLB
SCHEMBL34461758 0.74 TRPA1 (0.45) TRPA1KMT2AKDM4ETP53MAPT
SCHEMBL34461760 0.73 GRIA1 (0.32) MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS WRN, POLR1A, REV1 TRPA1 3662/4885MEN1 897/4885KMT2A 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback